Background. Fetal bone effects of maternal tenofovir use have not been well studied. We sought to compare whole-body bone mineral content (BMC) of newborns exposed vs not exposed to tenofovir in utero.
Tenofovir disoproxil fumarate (TDF), in combination with other antiretroviral drugs, is preferred initial therapy for adults with human immunodeficiency virus (HIV) infection because of its documented safety and efficacy [1, 2] . However, TDF has been associated with loss of bone mineral density (BMD) in adults [3] [4] [5] and children with HIV infection [6] and in adults taking TDF to prevent HIV infection [7, 8] . The clinical consequences of TDF-associated bone loss are less certain, but TDF use was a risk factor for bone fracture in adults with HIV infection in some studies [9, 10] .
TDF has been increasingly prescribed for pregnant women [11] . Both the World Health Organization (WHO) and US guidelines recommend TDF as a preferred antiretroviral agent in pregnancy [1, 12] . However, primate studies have demonstrated impaired fetal growth and bone mineralization after maternal tenofovir administration during late pregnancy [13] [14] [15] . Some [16, 17] , but not all [18] , human studies have suggested a potential adverse effect of maternal TDF use on infant growth. However, studies evaluating infant bone outcomes after intrauterine tenofovir exposure have been limited [19] .
In the present study, we aimed to evaluate the effects of maternal TDF use on infant bone mineral content (BMC).
METHODS

Study Participants
The source population for the present tenofovir substudy is the Surveillance Monitoring for ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study. SMARTT was designed to study the effect of antenatal and postnatal antiretroviral exposure on childhood outcomes in HIV-exposed but uninfected (HEU) children. Since 2007, SMARTT has been enrolling HEU infants during pregnancy or within 72 hours of birth from 14 clinical sites in the mainland United States and Puerto Rico. The standard of care at all sites is formula-feeding. Infants with HIV infection are excluded.
SMARTT participants were eligible for this cross-sectional tenofovir substudy if they were singleton pregnancies born at ≥36 weeks gestation and met the following criteria for tenofovir exposure: maternal receipt of TDF for ≥8 weeks in the third trimester of pregnancy (tenofovir-exposed) or no maternal receipt of TDF during the pregnancy (tenofovir-unexposed). Infants not continuing to meet these eligibility criteria at birth were excluded.
Medical History and Anthropometrics
Maternal sociodemographic data and information on substance use during the current pregnancy were obtained by self-report. Maternal medical history abstracted from the medical chart included pregnancy complications, infections, antiretroviral drugs and dates received, first and last CD4+ T-lymphocyte (CD4) count/percent and HIV viral load during the current pregnancy, delivery mode, and gestational age. Infant medical history and birthweight were abstracted from the infant's chart.
Infant weight and length were measured at the entry visit by trained personnel using standard methods previously described [20] . Each measurement was obtained 3 times and the average computed. Weight and length Z-scores were calculated based on the Centers for Disease Control and Prevention 2000 normative data [21] for infants born ≥37 weeks gestation and based on preterm infant normative data for infants born <37 weeks gestation [22] .
Dual-Energy X-Ray Absorptiometry
Infant dual-energy X-ray absorptiometry (DXA) scans were attempted within 4 (allowed up to 5) weeks of birth on a Hologic scanner (Delphi A, Discovery A, Discovery W, QDR4500A) using infant whole-body mode. DXA results included wholebody and whole-body less head measures of BMC, BMD, and total mass. To generate whole-body less head results, a custom subregion was created to divide the head from the rest of the body. Acceptable images were free of artifacts, contained the entire body of the infant, and had minimal movement distortion. A European Spine Phantom was circulated to all sites to ensure calibration among scanners. All scans were analyzed centrally by an International Society for Clinical Densitometry-certified bone densitometry technologist at the Tufts University Body Composition Analysis Center using Hologic APEX software version 13.4.
One DXA trainer traveled to sites that did not have personnel with prior experience in performing infant DXA scans (13/14) to train site technicians. Detailed instructions for performing infant whole-body DXA scans were provided in a manual of operations. The undressed infant (cotton shirt and diaper allowed) was swaddled and not sedated. Up to 3 scan attempts were permitted.
Outcome and Exposure Measures
The primary objective was to compare the mean BMC of tenofovir-exposed infants to that of tenofovir-unexposed infants. The primary BMC outcome was whole-body BMC (with head), but whole body BMC less head was also evaluated.
Potential Confounders
Potential confounding maternal factors included age, race/ethnicity, tobacco use during pregnancy, delivery in summer/fall vs winter/spring [23] , CD4% and HIV viral load before starting antiretroviral regimen, and other antiretroviral medications received during the pregnancy. Infant factors considered as risk factors for the outcome were sex, race/ethnicity, body length and weight, gestational age, age at DXA, whole-body mass with and less head (by DXA), and whole-body lean mass with and less head (by DXA). The gestational age at birth and age at DXA were included because BMC accrues rapidly during late fetal and neonatal periods.
Statistical Analyses
Target enrollment was set at 75 per group to ensure at least 63 evaluable participants per group. A sample size of 63 per group would allow detection of a difference of 0.5 standard deviations (SD) of mean whole-body BMC between groups, assuming 80% power and a 2-sided alpha of 0.05.
Differences in continuous variables and categorical variables between the groups were compared using Wilcoxon and χ 2 tests, respectively. For unadjusted BMC analyses, we compared mean BMC (with and less head) between groups. We then performed multivariable linear regression analysis to evaluate differences in BMC between groups, adjusted for potential confounders. All models were adjusted for clinical site, infant length, gestational age, age at DXA, and maternal tobacco use anytime during pregnancy. In addition, we considered the following potential covariates: infant whole-body mass with and less head from DXA; whole-body lean mass with and less head from DXA; and maternal height, prepregnancy weight, and body mass index. These potential confounders were included if the univariate association with BMC was P < .2 and retained in the model if the effect estimate changed by >10%. We fit models separately for whole-body BMC with and less head. We also conducted subgroup and sensitivity analyses to explore potential effects of other drugs in the maternal antiretroviral regimen.
We were unable to adjust for confounding by indication because maternal CD4 and viral load values before antiretroviral therapy (ART) initiation were missing for many women, and reasons for maternal regimen choice were not collected. We did not include CD4 and viral load values from the third trimester of pregnancy in the models because these might be the result of the exposure and on the causal pathway between maternal TDF use and infant BMC. However, we evaluated the associations of CD4% and viral load with the BMC outcomes.
All analyses were performed using SAS 9.2.
RESULTS
Study Population
Of 195 enrolled infants, 21 were no longer eligible at birth for the following reasons: gestational age <36 weeks (N = 16, including 1 fetal demise), born at another hospital (N = 1), stillborn (N = 1), loss of maternal custody (N = 1), and disqualifying change in maternal antiretroviral regimen during pregnancy (N = 2; Figure 1 ). No infant was excluded because of HIV infection. Of the 174 who were eligible, 126 enrolled before delivery, 37 were enrolled by age 2 days, 24 between ages 3 and 14 days, and 8 between ages 15 and 22 days. Evaluable DXA scans were obtained on the first scan attempt in 81 infants, the second attempt in 38 infants, and the third attempt in 24 infants. DXA scans were performed at a median age of 15 days overall, but at a median of 13 days in tenofovir-exposed infants and 19 days in unexposed infants (P < .001).
Characteristics of Mothers and Infants
Mothers who used TDF were more likely to be married (31% vs 22%; P = .035) and use a boosted protease inhibitor (PI) (84% vs 62%; P = .004). There were significant differences in the distribution of participants by tenofovir exposure across clinical sites (P < .001). The 2 groups of mothers did not differ on race/ethnicity, summer/fall delivery, high school education, income, or substance use during pregnancy (Table 1) . Mothers received diverse combinations of antiretroviral drugs, including 13 combinations for women who used TDF and 18 combinations for women who did not use TDF (Table 2) . Gestational age at birth was 36 to <37 weeks for 5 (7%) tenofovir-exposed infants and 4 (6%) tenofovir-unexposed infants. Tenofovir-exposed infants did not differ from unexposed infants with respect to race/ethnicity, gestational age at birth, or length or weight Z-scores (Table 1) .
Mean Bone Mineral Content by Tenofovir Exposure
The mean (SD) whole-body BMC of infants exposed to tenofovir was 56.0 (11.8) g compared with 63.8 (16.6) g for unexposed infants (P = .002; Table 3 ). This unadjusted difference of 7.8 g in BMC represents a difference of 12.2% and 0.5 SD between exposure groups. For whole-body BMC less head, the mean (SD) Figure 1 . Participants were enrolled 2 April 2011 to 4 June 2013 during pregnancy (gestation age ≥23 weeks) through 2 weeks after birth. Eligibility was confirmed at birth for those enrolled before birth; 21 infants were excluded for the following reasons: gestational age less than 36 weeks (N = 16, 1 of whom was fetal demise), born at another hospital (N = 1), stillborn (N = 1), mother lost custody of child (N = 1), disqualifying change in maternal antiretroviral regimen during pregnancy (N = 2). Abbreviations: DXA, dual-energy X-ray absorptiometry; TDF, tenofovir disoproxil fumarate. was 33.3 (7.3) g in the tenofovir-exposed group compared with 36.3 (9.7) g in the unexposed group (P = .038), representing a difference of 8.3% and 0.4 SD between exposure groups.
Adjusted Difference in Whole-Body Bone Mineral Content by Tenofovir Exposure
We fit a linear regression model to determine the mean difference in whole-body BMC between the tenofovir-exposed and tenofovir-unexposed infants, adjusted for potential cofactors. Our final model was adjusted for maternal age at delivery, use of tobacco during pregnancy, infant race (black vs non-black), gestational age, length, age at DXA scan, and clinical site ( Table 4 ). The adjusted mean whole-body BMC (with head) was 5.3 g lower (95% confidence interval [CI], −9.5, −1.2; P = .013) in the tenofovir-exposed compared with unexposed infants. When we fit the model for whole-body BMC less head, adjusted for the same factors, the mean whole-body BMC was 1.9 g lower (95% CI, −4.5, .7; P = .15) in the tenofovir-exposed compared with the unexposed infants.
Including boosted PI exposure in the models had a minimal impact on the estimate of the tenofovir effect. Duration of maternal TDF use was not associated with mean whole-body BMC in a multivariate model limited to tenofovir-exposed infants (P = .81).
Because triple nucleoside reverse transcriptase inhibitor therapy was a nonconventional ART regimen and was limited to the tenofovir-unexposed infants, we refit our model by adjusting for covariates without these 16 participants. In this model, BMC with head was 6.5 g lower in the tenofovir exposed infants (95% CI, −10.9; −2.2, P = .004). To exclude the possibility that atazanavir, a drug often prescribed with TDF, might drive the observed negative effect on BMC, we also performed a subgroup analysis that included only infants without atazanavir exposure (n = 91). In this smaller sample, the tenofovir effect persisted with an even larger effect size of −7.5 g (95% CI, −13.3, −1.7; P = .012).
Maternal CD4 Values and Viral Load
CD4 values were available for 107 women and viral loads were available for 112 women in the third trimester. There were no differences between the groups in the proportion with CD4 ≥ 500 cells/mm 3 (57% vs 41%; P = .11) or with viral load ≥400 copies/ mL (10% vs 10%; P = .95; Table 1 ). There was also no significant correlation between CD4% or viral load in the third trimester and BMC. For whole-body BMC with head, the correlations were r = 0.12 (P = .21) for CD4% and r = 0.15 (P = .13) for viral load. For whole-body BMC less head, the correlations were r = 0.12 (P = .21) for CD4% and r = 0.09 (P = .33) for viral load.
DISCUSSION
Infants with in utero tenofovir exposure had a significantly lower BMC than infants without in utero tenofovir exposure. c Missing income data for 9 tenofovir-unexposed and 2 tenofovir-exposed groups.
The magnitude and significance of this difference remained robust despite adjustment for factors expected to affect neonatal BMC. This finding is consistent with observations in animal studies and strongly supports a long-standing concern about potential adverse effects of maternal TDF on offspring bone mineral status [24] . The magnitude of the mean BMC difference (12% or 0.5 SD) between tenofovir-exposed and tenofovir-unexposed infants should be considered relative to other studies of bone effects of tenofovir and other exposures. In a double-blind, placebocontrolled randomized clinical trial of TDF-emtricitabine in HIV-uninfected adults, spine BMD declined 0.13 SD in the TDF-emtricitabine arm but increased by 0.13 SD in the placebo arm by week 24, for a net difference of 0.26 SD [7] . In a trial that randomized HIV-infected adults to initiate a TDF-containing regimen vs an abacavir-containing regimen (without TDF), spine BMD declined by 0.22 SD in the TDF arm but only by 0.11 SD in the abacavir arm at week 48 [4] . In a trial that randomized preterm infants to receive preterm formula vs standard term-infant formula, whole-body BMC was 18% and 19% higher in the preterm formula-fed infants after 2 and 4 months, respectively; the corresponding differences when BMC was corrected for body weight were 9% and 7%, respectively [25] . Thus, the magnitude of difference in the present study appears to be larger than the effect sizes reported for adults who take TDF and in infants with nutritional interventions.
While the association of maternal TDF during pregnancy with lower infant BMC in our study is concerning, the need to modify current WHO and US recommendations for TDF in pregnancy will depend on whether the effect persists and whether there are clinical consequences. The present study provides strong evidence of a biologic effect of maternal TDF on infant bone. However, the lack of infant BMC reference standards makes it difficult to determine if the lower BMC in tenofovir-exposed infants is abnormal. In a large study of healthy, full-term (37-42 weeks gestation) Canadian infants in whom whole-body BMC measurements were obtained within 2-4 weeks of birth using Hologic scanners, the mean (SD) whole-body BMC (with head) was 76.0 (14.2) g and mean (SD) whole-body BMC per body weight was 20.7 (2.5) g/kg [23] , substantially greater than the corresponding unadjusted measurements for both exposure groups in the present study (Table 3) . These relatively large differences are unlikely the result of the lower gestational age in the present 11 (16) Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; DRV, darunavir; ETR, etravirine; FPV, fosamprenavir; FTC, emtricitabine; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NVP, nevirapine; r, ritonavir (boosting dose); RAL, raltegravir; RPV, rilpivirine; SQV, saquinavir; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine. a In the tenofovir-exposed group, 29 (39%) women were already receiving their TDF-containing antiretroviral regimen when they became pregnant, while 11 (15%), 30 (41%), and 4 (5%) started that regimen in the first, second, and third trimesters, respectively. b Other regimens used by 1 (1%) woman in tenofovir-exposed group included: TDF-FTC-ABC-RAL, TDF-FTC-FPVr, TDF-FTC-NVP, TDF-FTC-SQVr, TDF-ZDVATVr, TDF-FTC-RAL-DRVr. c In the tenofovir-unexposed group, 18 (26%) women were already receiving their antiretroviral regimen prior to pregnancy, while 17 (25%), 31 (45%), and 3 (4%) started their pregnancy regimen in the first, second, and third trimesters, respectively. d Other regimens used by 1 (1%) woman in tenofovir-unexposed group included: ABC-3TC-ATV, ZDV-3TC-ATVr, ZDV-3TC-NVP, ZDV-3TC-MVC, ETR-RAL-DRVr, ABC-3TC-ZDV-NVP, ABC-3TC-ZDV-RAL, ZDV-3TC RAL-LPVr, ZDV-3TC-RAL-MVC-DRVr, ZDV-3TC-ETR-DRVr, 3TC-LPVr. study (mean 38.2 weeks vs 39.3 weeks in the Canadian study); in our study, each additional week of gestational age was associated with an adjusted mean BMC increase of 2.1 g ( Table 4 ). The difference in participant racial composition between these studies is also not likely to explain the differences since BMC is similar for black and white young infants [26] . Lower BMC and BMD are well-established risk factors for bone fracture in adults [27] and children [28, 29] . Low BMC at birth may increase fracture risk in infancy and early childhood and also have longer-term implications. Failure to reach expected peak bone mass in early adulthood is a risk factor for osteoporosis in later life [30] . Preterm birth and low birthweight increase the risk of lower adult bone mass and fracture, suggesting that intrauterine exposures may have lifelong bone consequences [31] . Maternal sun exposure, vitamin D status, magnesium intake, and other dietary factors during pregnancy correlate with BMC and BMD outcomes in offspring 9 years later [32] , providing evidence that time-limited exposures during pregnancy can lead to long-term bone consequences. The potential clinical consequences of lower BMC in the present study will require longitudinal evaluation.
Although tenofovir was the primary exposure of interest, the potential effect on neonatal bones of other antiretroviral drugs was considered. As a class, PIs have been associated with low BMD in some, but not all, studies of children [33, 34] and adults [5, 35] with HIV infection. In addition, higher tenofovir levels (but lower PI levels) occur when tenofovir is co-administered with atazanavir or other PIs [36, 37] . However, adjustment for PIs as a class did not affect the relationship of tenofovir exposure to infant BMC in the present study. Furthermore, subgroup analysis provided evidence that atazanavir alone, the PI most commonly used with TDF in this study, did not explain the association between maternal TDF and lower infant BMC. The relatively small sample size, heterogeneity of antiretroviral drug regimens, and imbalance in antiretroviral drugs and drug classes by concurrent tenofovir exposure prevented further analysis of the effect of these other drugs on infant BMC outcomes. More data are needed about the potential for PIs in pregnancy to affect neonatal BMC.
Vitamin D, parathyroid hormone, and diet were not assessed in the mothers in the present study. Vitamin D insufficiency is common in people with HIV infection, and TDF leads to parathyroid hormone elevations that are mitigated by vitamin D supplementation [38] . Recent data suggest that vitamin D supplementation in adults initiating ART can prevent ARTassociated BMD loss [39] . The role of vitamin D levels in the association between maternal TDF and infant bone outcomes should be explored in future studies. Maternal or infant vitamin D supplementation may be a strategy to counteract the infant bone effects of intrauterine tenofovir exposure, though infant vitamin D supplementation has not improved bone outcomes in trials of preterm infants or healthy breastfeeding infants [40, 41] . Infant physical therapy interventions may be another option for improving postnatal bone growth and bone mass accrual [42] .
Limitations of this study include the potential for residual confounding and the lack of criteria for defining abnormal and normal BMC in infants. While preterm birth has not been associated with tenofovir exposure and therefore would not be on the causal pathway, we excluded preterm infants because preterm birth results in lower BMC. Thus, findings may not be generalizable to preterm infants. Very few women in this study used non-nucleoside reverse transcriptase inhibitors (NNRTIs), preventing evaluation of potentially different effects of TDF when used in a regimen with NNRTIs. This cross-sectional study does not provide information about longitudinal BMC changes or later risk of bone fragility. However, since infants in this substudy are part of the ongoing SMARTT cohort study, further follow-up will be possible as the infants grow and develop. The International Maternal Pediatric AIDS Adolescent Clinical Trials network has completed enrollment in the multisite study (P1084s) in Africa that measures BMC at birth and again at age 26 weeks in infants whose mothers were randomized to receive ART regimens with or without tenofovir during pregnancy. Results from this study are expected in 2016 [43] . TDF remains an important part of highly efficacious antiretroviral regimens for treating women with HIV infection and for preventing infant HIV. The association of maternal TDF with lower infant BMC in the present study will need confirmation in other studies that can also evaluate persistence and clinical implications of lower infant BMC before recommendations for TDF use in pregnancy are modified.
Notes
